Format

Send to

Choose Destination
Health Aff (Millwood). 2015 Oct;34(10):1666-74. doi: 10.1377/hlthaff.2014.1193.

Broad Hepatitis C Treatment Scenarios Return Substantial Health Gains, But Capacity Is A Concern.

Author information

1
Karen Van Nuys is a senior research economist at Precision Health Economics, in Los Angeles, California.
2
Ronald Brookmeyer is a professor of biostatistics at the University of California, Los Angeles.
3
Jacquelyn W. Chou is an associate director and research scientist at Precision Health Economics.
4
David Dreyfus is a data scientist at Arete Analytics, in Andover, Massachusetts.
5
Douglas Dieterich is a professor of medicine in the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai, in New York City.
6
Dana P. Goldman (dana.goldman@usc.edu) is the Leonard D. Schaeffer Chair and director of the Schaeffer Center for Health Policy and Economics at the University of Southern California, in Los Angeles.

Abstract

Treatment of hepatitis C virus, the most common chronic viral infection in the United States, has historically suffered from challenges including serious side effects, low efficacy, and ongoing transmission and reinfection. Recent innovations have produced breakthrough therapies that are effective in more than 90 percent of patients. These treatments could dramatically reduce the virus's prevalence but are costly. To quantify the benefit of these treatments to society, including the value of reduced transmission, we estimated the effects of several hepatitis C treatment strategies on cost and population health. Treating patients at all disease stages could generate $610-$1,221 billion in additional quality-adjusted life-years, plus an additional $139 billion in saved medical expenditures over fifty years, and minimize the disease burden, but up-front treatment costs would exceed $150 billion. An intermediate scenario--treating 5 percent of the infected population annually, regardless of patients' disease stages--would also return substantial benefits and would be much more affordable under current financing schemes.

KEYWORDS:

Access To Care; Epidemiology; Health Economics; Health Promotion/Disease Prevention; Health Spending

PMID:
26438742
DOI:
10.1377/hlthaff.2014.1193
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center